IIID, Inc.
Identifying the TCR–peptide–HLA triplets that drive immune disease.
Three things have to come together for a T cell to attack human tissue: a receptor, a peptide, and the HLA molecule that presents it. Name all three and a hypersensitivity reaction, an autoimmune lesion or a rejected graft stops being idiopathic. Naming all three is what we do.
The triplet
Most immunology reports one element at a time: an HLA risk allele from a genetic association, a T cell clone from a sequencing study, a peptide from a binding assay. The interesting biology lives in the combination.
-
T cell receptor
The receptor doing the recognizing.
-
Peptide
The fragment being recognized.
-
HLA
The molecule presenting it.
What we work on
Our work starts from the Keystone Epitope Theory, set out in two 2026 reviews in Pathogens and Immunity. Persistent, human-adapted pathogens focus immune memory on a small number of conserved epitopes in the tissues where they are controlled. That focusing is protective against the pathogen, and it is also the reason a drug, a graft or a self-protein that resembles one of those epitopes can provoke disease.
We search for the resemblances: viral epitope seeds matched against human proteomes under HLA restriction, filtered by what a T cell receptor actually contacts and by where the candidate protein is expressed.
Read more about the theory- Application areas
- Drug hypersensitivity, autoimmunity, transplantation, vaccine design.
- Contact
- mail@iiid.us
- Entity
- IIID, Inc. is a Delaware corporation.
UEI D7X2CNJWJQC9
Franklin, Tennessee, USA